Literature DB >> 20960311

A quantitative assay for measuring of bovine immunodeficiency virus using a luciferase-based indicator cell line.

Xue Yao1, Hong-yan Guo, Chang Liu, Xuan Xu, Jian-sen Du, Hao-yue Liang, Yun-qi Geng, Wen-tao Qiao.   

Abstract

In order to quantitate the bovine immunodeficiency virus (BIV) infection in vitro, a BIV indicator cell line (BIVL) was established by transfecting baby hamster kidney cells with reporter plasmids containing the firefly luciferase gene driven by a BIV long terminal repeat promoter. The BIV activates promoter activity of the LTR to express luciferase upon infection. BIV infection could therefore by quantified by detection of luciferase activity. Compared to standard assays used to detect BIV infection, the BIVL-based assay is 10 times more sensitive than the the CPE-based assay, and has similar sensitivity with the viral capsid protein Western blot assay. BIV indicator cell line could detect BIV infection specifically. Luciferase activity of BIV infected BIVL cells showed a time dependent manner, and 60 h post infection is the optimal time to detect BIV infection. Luciferase activity of BIVL cells correlates with the BIV capsid protein expression. Moreover, a linear relationship was found between MOI and the activated intensity of luciferase expression. In brief, the BIV indicator cell line is an easy, robust and quantitive method for monitoring BIV infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960311      PMCID: PMC8227901          DOI: 10.1007/s12250-010-3109-1

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  23 in total

1.  The catalytic properties of the recombinant reverse transcriptase of bovine immunodeficiency virus.

Authors:  Orna Avidan; Ron Bochner; Amnon Hizi
Journal:  Virology       Date:  2006-05-02       Impact factor: 3.616

2.  T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.

Authors:  Christina Ochsenbauer-Jambor; Jennifer Jones; Marintha Heil; Kenneth P Zammit; Olaf Kutsch
Journal:  Biotechniques       Date:  2006-01       Impact factor: 1.993

3.  Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases.

Authors:  Chi Ching Mak; Ashraf Brik; Danica L Lerner; John H Elder; Garrett M Morris; Arthur J Olson; Chi-Huey Wong
Journal:  Bioorg Med Chem       Date:  2003-05-01       Impact factor: 3.641

Review 4.  Development of the bovine immunodeficiency-like virus as a model of lentivirus disease.

Authors:  M A Gonda; M S Oberste; K J Garvey; L A Pallansch; J K Battles; D Y Pifat; J W Bess; K Nagashima
Journal:  Dev Biol Stand       Date:  1990

5.  Binding of Tat to TAR and recruitment of positive transcription elongation factor b occur independently in bovine immunodeficiency virus.

Authors:  M Barboric; R Taube; N Nekrep; K Fujinaga; B M Peterlin
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds.

Authors:  Jennifer Jones; John Rodgers; Marintha Heil; Jori May; Lucile White; Joseph A Maddry; Thomas M Fletcher; George M Shaw; John L Hartman; Olaf Kutsch
Journal:  Assay Drug Dev Technol       Date:  2007-04       Impact factor: 1.738

7.  Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.

Authors:  Guangwei Yang; Elijah Paintsil; Ginger E Dutschman; Susan P Grill; Chuan-Jen Wang; Jimin Wang; Hiromichi Tanaka; Takayuki Hamasaki; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

8.  Characterization of early pathogenic effects after experimental infection of calves with bovine immunodeficiency-like virus.

Authors:  S Carpenter; L D Miller; S Alexandersen; C A Whetstone; M J VanDerMaaten; B Viuff; Y Wannemuehler; J M Miller; J A Roth
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay.

Authors:  Jean-Michel Garcia; Anhui Gao; Pei-Lan He; Joyce Choi; Wei Tang; Roberto Bruzzone; Olivier Schwartz; Hugo Naya; Fa-Jun Nan; Jia Li; Ralf Altmeyer; Jian-Ping Zuo
Journal:  Antiviral Res       Date:  2008-12-30       Impact factor: 5.970

10.  Activation of bovine immunodeficiency-like virus expression by bovine herpesvirus type 1.

Authors:  Y Geng; F Kashanchi; C Wood
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

View more
  2 in total

1.  The effect of bovine BST2A1 on the release and cell-to-cell transmission of retroviruses.

Authors:  Zhibin Liang; Yang Zhang; Jie Song; Hui Zhang; Suzhen Zhang; Yue Li; Juan Tan; Wentao Qiao
Journal:  Virol J       Date:  2017-09-06       Impact factor: 4.099

2.  Bovine HEXIM1 inhibits bovine immunodeficiency virus replication through regulating BTat-mediated transactivation.

Authors:  Hong-yan Guo; Yong-gang Ma; Yuan-ming Gai; Zhi-bin Liang; Jing Ma; Yang Su; Qi-cheng Zhang; Qi-min Chen; Juan Tan
Journal:  Vet Res       Date:  2013-03-27       Impact factor: 3.683

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.